Pluristem Therapeutics, Inc. (PSTI): Price and Financial Metrics

Pluristem Therapeutics, Inc. (PSTI): $2.69

0.06 (+2.28%)

POWR Rating

Component Grades













Add PSTI to Watchlist
Sign Up

Industry: Biotech


of 476

in industry

PSTI Stock Summary

  • The ratio of debt to operating expenses for Pluristem Therapeutics Inc is higher than it is for about merely 7.8% of US stocks.
  • With a price/sales ratio of 7,556.28, Pluristem Therapeutics Inc has a higher such ratio than 99.75% of stocks in our set.
  • As for revenue growth, note that PSTI's revenue has grown -54% over the past 12 months; that beats the revenue growth of merely 4.59% of US companies in our set.
  • Stocks that are quantitatively similar to PSTI, based on their financial statements, market capitalization, and price volatility, are VTVT, AIKI, ATOM, SPCE, and AQB.
  • Visit PSTI's SEC page to see the company's official filings. To visit the company's web site, go to

PSTI Stock Price Chart Interactive Chart >

Price chart for PSTI

PSTI Price/Volume Stats

Current price $2.69 52-week high $11.85
Prev. close $2.63 52-week low $2.44
Day low $2.58 Volume 130,500
Day high $2.69 Avg. volume 416,299
50-day MA $2.72 Dividend yield N/A
200-day MA $3.82 Market Cap 86.35M

Pluristem Therapeutics, Inc. (PSTI) Company Bio

Pluristem Therapeutics Inc. operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. The company was founded in 2001 and is based in Haifa, Israel.

PSTI Latest News Stream

Event/Time News Detail
Loading, please wait...

PSTI Latest Social Stream

Loading social stream, please wait...

View Full PSTI Social Stream

Latest PSTI News From Around the Web

Below are the latest news stories about Pluristem Therapeutics Inc that investors may wish to consider to help them evaluate PSTI as an investment opportunity.

JPMorgan Chase & Co. Sells 34,680 Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI)

JPMorgan Chase & Co. reduced its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 46.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,761 shares of the biotechnology companys stock after selling 34,680 shares during the quarter. JPMorgan Chase & Co. []

Transcript Daily | November 16, 2021

JPMorgan Chase & Co. Lowers Position in Pluristem Therapeutics Inc. (NASDAQ:PSTI)

JPMorgan Chase & Co. cut its holdings in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 46.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,761 shares of the biotechnology companys stock after selling 34,680 shares during the quarter. JPMorgan Chase & []

Dakota Financial News | November 16, 2021

Reviewing Pluristem Therapeutics (NASDAQ:PSTI) & Axcella Health (NASDAQ:AXLA)

Pluristem Therapeutics (NASDAQ:PSTI) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Volatility & Risk Pluristem Therapeutics has a beta of 2.25, indicating that its stock price []

Transcript Daily | November 15, 2021

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on muscle regeneration following hip fracture surgery on November 22 at 9:15am EST HAIFA, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnologycompany announced today that its multinational Phase IIImulticenter, randomized, d

Yahoo | November 15, 2021

Pluristem Therapeutics (NASDAQ:PSTI) Posts Earnings Results, Beats Expectations By $0.05 EPS

Pluristem Therapeutics (NASDAQ:PSTI) announced its earnings results on Monday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Zacks consensus estimate of ($0.41) by $0.05, Fidelity Earnings reports. PSTI stock traded down $0.17 during midday trading on Wednesday, reaching $2.93. The stock had a trading volume of 4,768 shares, compared to []

Dakota Financial News | November 10, 2021

Read More 'PSTI' Stories Here

PSTI Price Returns

1-mo 1.51%
3-mo -9.12%
6-mo -29.58%
1-year -71.92%
3-year -75.09%
5-year -82.19%
YTD -61.95%
2020 79.44%
2019 -50.13%
2018 -42.75%
2017 -3.50%
2016 26.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7781 seconds.